Oncogenic transformation can orchestrate immune evasion and inflammation in human mesenchymal stem cells independently of extrinsic immune-selective pressure

Cancer Research

Volumn 75, Issue 15, 2015, Pages 3032-3042

  Miranda, Alex ^a   Funes, Juan M ^b   Sánchez, Nilda ^a   Limia, Celia M ^a,c   Mesa, Mónica ^a   Quezada, Sergio A ^b   Pérez, Rolando ^a   De León, Joel ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; GENETIC TRANSFORMATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ESCAPE; ANIMAL; CELL CULTURE; DRUG SCREENING; IMMUNE EVASION; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; HUMANS; IMMUNE EVASION; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-1BETA; MESENCHYMAL STROMAL CELLS; MICE, NUDE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942904033     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3276     Document Type: Article

References (39)

1. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
2. Schreiber RD, Old LJ, Smyth MJ Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70.
3. Mantovani A, Allavena P, Sica A., Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44.
4. Allavena P, Garlanda C, Borrello M.G., Sica A., Mantovani A. Pathways connecting inflammation and cancer. CurrOpin Genet Dev 2008; 18: 3-10.
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2011; 140: 883-99.
6. Funes JM, Quintero M, Henderson S., Martinez D, Qureshi U, Westwood C., et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A 2007; 104: 6223-8.
7. Nicola MD, Carlo-Stella C. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Transplantation 2002; 99: 3838-43.
8. Tse WT, Pendleton JD, Beyer W.M., Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389-97.
9. Karnoub AE, Dash AB, Vo A.P., Sullivan A., Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 4: 557-63.
10. Dwyer RM, Potter-Beirne SM, Harrington K.A., Lowery AJ, Hennessy E, Murphy JM, et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007; 4: 5020-7.
11. Galiè M, Konstantinidou G, Peroni D, Scambi I, Marchini C, Lisi V, et al. Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene 2008; 27: 2542-51.
12. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003; 3: 685-94.
13. Sánchez N., Miranda A, Funes J.M., Hevia G., Pérez R, de León J. Oncogenic transformation tunes the cross-talk between mesenchymal stem cells and T lymphocytes. Cell Immunol 2014; 289: 174-84.
14. Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 2012; 18: 128-34.
15. Ramasamy R, Tong CK, Seow H.F., Vidyadaran S., Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T-cell proliferation but not its effector function. Cell Immunol 2008; 251: 131-6.
16. Ren G, Su J, Zhang L., Zhao X, Ling W, L'huillie A, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27: 1954-62.
17. Krampera M, Cosmi L, Angeli R., Pasini A, Liotta F, Andreini A., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-98.
18. Bach EA, Aguet M, Robert D, Schreiber RD The IFN-γ receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997; 15: 563-91.
19. Der SD, Zhou A, Williams B.R., Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95: 15623-8.
20. Aggarwal S, Pittenger MF Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-22.
21. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
22. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-50.
23. Nurieva XL, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 2009; 229: 88-100.
24. Khalili JS, Liu S, Rodríguez-Cruz TG. Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012; 18: 5329-40.
25. Vesely MD, Kershaw MH, Schreiber R.D., Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-71.
26. Hirokazu M. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482: 400-4.
27. Rabinovich GA, Gabrilovich D, Sotomayor EM Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-96.
28. Garrido F, Cabrera T, Aptsiauri N. Hard and soft lesions underlying the HLA Class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010; 127: 249-56.
29. Kaplan DH, Shankaran V, Dighe A.S., Stockert E., Aguet M, Old LJ, et al Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95:7556-61.
30. Grazia M, Degl D, Pierotti MA Inflammation and cancer: the oncogene-driven connection. Cancer Lett 2008; 267: 262-70.
31. Kaluz S, Van Meir EG. At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop. J Mol Med 2011; 89: 91-4.
32. Jung YJ, Isaacs JS, Lee S, Trepel J., Neckers L. IL-1β mediated up-regulation of HIF-1α via NFkβ/Cox2 pathway identifies HIF-1α as a critical link between inflammation and cancer. FASEB J 2003; 17: 2115-7.
33. Apte RN, Dotan S, Elkabets M., White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006; 25: 387-408.
34. Tu S, Bhagat G, Cui G., Takaishi S, Kurt-Jones EA, Rickman B, et al Over-expression of interleukin-1β induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14:408-19.
35. Wang L, Zhang L, Wu J. IL-1 β-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis. Cancer Res 2014; 74: 4720-30.
36. Iliopoulos D, Hirsch H, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139: 693-706.
37. Nazarenko I, Marhaba R, Reich E., Voronov E, Vitacolonna M, Hildebrand D., et al. Tumorigenicity of IL-1α- and IL-1β-deficient fibrosarcoma cells. Neoplasia 2008; 10: 549-62.
38. Vale T, Ngo T, White M., Lipsky P. Raf-induced transformation requires an interleukin 1 autocrine loop. Cancer Res 2001; 61: 602-7.
39. Collado M, Gil J, Efeyan A., Guerra C, Schuhmacher AJ, Barradas M, et al Tumour biology: senescence in premalignant tumours. Nature 2005; 436:642.